Literature DB >> 20865874

Intraoperative nitrous oxide as a preventive analgesic.

D K Stiglitz1, L N Amaratunge, A H Konstantatos, D E Lindholm.   

Abstract

Preventive analgesia is defined as the persistence of the analgesic effects of a drug beyond the clinical activity of the drug. The N-methyl D-aspartate receptor plays a critical role in the sensitisation of pain pathways induced by injury. Nitrous oxide inhibits excitatory N-methyl D-aspartate sensitive glutamate receptors. The objective of our study was to test the efficacy of nitrous oxide as a preventive analgesic. We conducted a retrospective analysis of data from a subset of patients (n = 100) randomly selected from a previous major multicentre randomised controlled trial on nitrous oxide (ENIGMA trial). Data analysed included postoperative analgesic requirements, pain scores and duration of patient-controlled analgesia during the first 72 postoperative hours. There was no significant difference in postoperative oral morphine equivalent usage (nitrous group 248 mg, no nitrous group 289 mg, mean difference -43 mg, 95% confidence interval 141 to 54 mg). However, patients who received nitrous oxide had a shorter duration of patient-controlled analgesia use (nitrous group 35 hours, no nitrous group 51 hours, mean difference -16 hours, 95% confidence interval -29 to -2 hours, P = 0.022). There was no difference in pain scores between the groups. The shorter patient-controlled analgesia duration in the nitrous oxide group suggests that intraoperative nitrous oxide may have a preventive analgesic effect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865874     DOI: 10.1177/0310057X1003800513

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  1 in total

1.  The effect of nitrous oxide anesthesia on early postoperative opioid consumption and pain.

Authors:  Andreas Duma; Daniel Helsten; Frank Brown; Michael M Bottros; Peter Nagele
Journal:  Reg Anesth Pain Med       Date:  2014 Jan-Feb       Impact factor: 6.288

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.